From the genetics of COVID-19, to cancer, to tonsils, this story is a wrap up of Scope's most read stories of 2021.
Stanford Medicine researchers conducted an experiment to find new genes that, when knocked out, boost immune cells' cancer-killing ability.
Stanford Medicine Scientists have devised a blood test to predict some cancer relapses after patients have already been treated.
Anthony Oro is devoted to understanding the origin of basal cell carcinomas. Now he's found how some become resistant to a common treatment.
As risk factors such as no health insurance and low income accumulate, colorectal cancer patients are less likely to finish chemotherapy.
Stanford Medicine researchers discover that certain proteins can predict survival for patients with a type of eye cancer.
A cancer survivor treated at Stanford has written a book to help kids facing stem cell transplant understand the procedure and approach it with courage.
People who have their first colonoscopy between the age of 45 and 49 halve their risk of subsequent colorectal cancers, a Stanford Medicine study has found.
Editor's update: Emily Ashkin is featured in a podcast from The Lasker Foundation. My legs were starting to ache from standing by my research poster …
Stanford Medicine magazine's most-read articles of 2020 were about COVID-19, grieving and chemo brain, a misunderstood side effect of chemotherapy.
ESPN told the story of Stanford football coach David Shaw donating stem cells to save his brother, who had a rare form of lymphoma.
Stanford researchers studied whether there was any pattern linking patients' racial, ethnic or socioeconomic status with which treatment they received.
Scientists created an algorithm that analyzes a cancer biopsy and pairs spatial information with gene expression to better understand the disease.
In breast and lung cancer patients with metastatic disease, seeds of metastasis were often planted before the primary tumor was diagnosed, a study finds.
Using microbubbles and ultrasound, researchers have created a cancer treatment that kills tumor cells and recruits immune cells to the tumor.
The experts on Stanford Medicine's molecular tumor board brainstorm new ways to attack individual patients' tumors at the genetic level.
